drugset / Trial / NCT01985373

Pharmacokinetics and Safety of IVIG Nanogam 100 mg/ml

NCT01985373

Phase 3 Completed 23 enrolled Prothya Biosolutions
NaSingle-groupOpen-labelTreatment

Summary

Intravenous immunoglobulin (IVIG) is used for treatment of a heterogeneous group of immune related disorders both as immune-replacement and immune-modulating therapy. Sanquin developed a 100 mg/ml IVIg product (Nanogam 100 mg/ml). Patient will receive one infusion with Nanogam 50 mg/ml as they used to (same dose) and subsequently 4 infusions with Nanogam 100 mg/ml (same dose). Aim is to show bioequivalency between the 50 mg/ml and the 100 mg/ml product of Sanquin.

Timeline

Start
2013-12
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 0.2 g/kg Intravenous
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 0.8 g/kg Intravenous